Company Filing History:
2 out of 151 
1 out of 16 Years Active: 2007-2015
Title: Seamus C Donnelly: Innovator in Inflammatory Disease Research
Introduction
Seamus C Donnelly is a notable inventor based in Dublin, Ireland. He has made significant contributions to the field of inflammatory diseases through his innovative research and patented inventions. With a total of 2 patents, Donnelly's work focuses on the genetic factors influencing inflammatory responses.
Latest Patents
Donnelly's latest patents include a groundbreaking discovery related to the Macrophage migration inhibitory factor (MIF) promoter polymorphism in inflammatory disease. This patent describes a novel CATT-tetranucleotide repeat polymorphism at position -817 of the human Mif gene, which functionally affects the activity of the MIF promoter in gene reporter assays. Four genotypes are identified, comprising 5, 6, 7, or 8-CATT repeat units. Notably, the 5-CATT allele exhibits the lowest level of basal and stimulated MIF promoter activity in vitro. The presence of this low-expressing 5-CATT repeat allele correlates with reduced disease severity in a cohort of rheumatoid arthritis patients. The patent also discloses methods, compositions, and apparatus for detecting this polymorphism and assessing predisposition to severe inflammatory diseases.
Career Highlights
Throughout his career, Seamus C Donnelly has worked with prominent companies in the biotechnology sector, including Baxalta GmbH and Cytokine Pharmasciences, Inc. His experience in these organizations has allowed him to advance his research and contribute to the understanding of inflammatory diseases.
Collaborations
Donnelly has collaborated with esteemed colleagues, including John A Baugh and Richard J Bucala. These partnerships have further enriched his research endeavors and have led to significant advancements in the field.
Conclusion
Seamus C Donnelly's innovative work in the area of inflammatory diseases has led to valuable patents and collaborations. His contributions continue to impact the scientific community and enhance our understanding of genetic factors in disease severity.